Neoadjuvant Therapy with Multikinase Inhibitors for Locally Advanced Differentiated Thyroid Cancer: A Systematic Review
Thyroid® · 2025-10 · 35 (10) · 1108-1119
DOI: 10.1177/10507256251367286 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Thyroid®, online erschienen am 13.08.2025. Verfasst von Justin Bauzon und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrine Surgery, Cleveland Clinic, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Neoadjuvant Therapy, Protein Kinase Inhibitors, Antineoplastic Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 70 Literaturangaben.
Abstract (Originalsprache)
Background
The use of multikinase inhibitors (MKIs) in thyroid cancer has been established to downsize and facilitate resection of poorly differentiated, differentiated high-grade, anaplastic, and medullary thyroid cancer. Case reports and case series have suggested the potential use of MKIs as neoadjuvant therapies for locally advanced differentiated thyroid cancer (DTC). Our objective was to review available studies and assess if neoadjuvant therapy with MKI can improve surgical and oncological outcomes in patients with locally advanced DTC.
Methods
A systematic search of four different databases (PubMed, Cochrane Library, Scopus, and EMBASE) with no time restrictions was performed to identify relevant observational studies evaluating patients with locally advanced DTC who received neoadjuvant therapy before surgery with MKI (PROSPERO ID: CRD420251012812).
Results
A total of 119 participants from 23 observational studies (12 case reports, 9 case series, and 2 prospective phase II studies) were included. Lenvatinib was the most frequently used MKI, followed by sorafenib. Tumor volume reduction ranged from 25% to 87%, and partial response rates ranged between 33.3% and 76.9%, whereas progressive disease was described only in seven cases. Of 114 patients with inoperable or potentially resectable tumors with associated high perioperative morbidity, 95 (83.3%) were able to undergo surgery.
Conclusions
Neoadjuvant MKIs in locally advanced DTC may improve resection rates. The overall low quality of evidence prompts further prospective studies to confirm these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrine Surgery, Cleveland Clinic, Cleveland, Ohio, USA.
- Department of Surgery, Hospital Angeles Morelia, Morelia, Mexico.
- Department of Surgery, Star Medica Morelia, Morelia, Mexico.
- Department of Surgery, University of Central Florida-HCA Healthcare, Orlando, Florida, USA.
- Department of Endocrinology, Cleveland Clinic, Cleveland, Ohio, USA.
- Department of Oncology, Cleveland Clinic, Cleveland, Ohio, USA.
ORCID-Profile: Justin Bauzon, Eddy Lincango, Rafael Perez-Soto, Gustavo Romero-Velez
Zitieren
APA
Bauzon, J., Ponce de Leon-Ballesteros, G., Lincango, E., Medina-Franco, H., Perez-Soto, R., Lashin, O., Geiger, J. L., Nasr, C., Shin, J., Siperstein, A., & Romero-Velez, G. (2025). Neoadjuvant Therapy with Multikinase Inhibitors for Locally Advanced Differentiated Thyroid Cancer: A Systematic Review. Thyroid®, 35(10), 1108-1119. https://doi.org/10.1177/10507256251367286
Vancouver
Bauzon J, Ponce de Leon-Ballesteros G, Lincango E, Medina-Franco H, Perez-Soto R, Lashin O, et al. Neoadjuvant Therapy with Multikinase Inhibitors for Locally Advanced Differentiated Thyroid Cancer: A Systematic Review. Thyroid®. 2025;35(10):1108-1119. doi:10.1177/10507256251367286
BibTeX
@article{Bauzon2025,
author = {Bauzon, Justin and Ponce de Leon-Ballesteros, Guillermo and Lincango, Eddy and Medina-Franco, Heriberto and Perez-Soto, Rafael and Lashin, Ossama and Geiger, Jessica L and Nasr, Christian and Shin, Joyce and Siperstein, Allan and Romero-Velez, Gustavo},
title = {Neoadjuvant Therapy with Multikinase Inhibitors for Locally Advanced Differentiated Thyroid Cancer: A Systematic Review},
journal = {Thyroid®},
year = {2025},
volume = {35},
number = {10},
pages = {1108--1119},
doi = {10.1177/10507256251367286}
}
EUVIMED